Methotrexate

WASHINGTON — In this video, Ambreesh Chawla, MD, summarizes salient and practice-changing presentations in rheumatoid arthritis from ACR Convergence 2024.

WASHINGTON — An early, 1-year course of methotrexate may prevent anti-citrullinated protein autoantibody-negative rheumatoid arthritis in high-risk patients with clinically suspect arthralgia, noted a presenter at ACR Convergence 2024.

WASHINGTON — Patients with autoimmune rheumatic diseases who withhold methotrexate for 2 weeks after receiving the recombinant herpes zoster vaccine demonstrate improved humoral response, according to data presented at ACR Convergence 2024.

WASHINGTON — Patients with polymyalgia rheumatica were more likely to discontinue steroids after treatment with sarilumab than methotrexate, according to data presented at ACR Convergence 2024.

The FDA has expanded the approval of an oral liquid methotrexate solution to include children and adolescents with polyarticular juvenile idiopathic arthritis and acute lymphoblastic leukemia, according to a press release.

Patients with rheumatoid arthritis and high rheumatoid factor demonstrate better clinical outcomes, and maintain drug concentration, when treated with certolizumab pegol vs. adalimumab, according to data published in Rheumatology.

Oral methotrexate in combination with usual analgesics significantly reduced knee osteoarthritis pain and stiffness, and improved function, vs. placebo, according to data published in Annals of Internal Medicine.

Upadacitinib shows superior clinical, radiographic and patient-reported outcomes in RA, and has a more favorable risk-benefit profile, compared with methotrexate over 5 years, according to data published in Arthritis Research & Therapy.

Olokizumab combined with methotrexate for the treatment of rheumatoid arthritis maintains its safety and efficacy profile through 106 weeks, according to data published in Annals of the Rheumatic Diseases.